蒙药巴特日七味丸治疗轻中度溃疡性结肠炎的研究

Efficacy of Mongolian medicine Bartezhi Qiwei Pill on mild to moderate ulcerative colitis

目的探讨蒙药巴特日七味丸治疗轻中度溃疡性结肠炎(UC)患者的临床疗效及可能机制。方法纳入2022年9月—2023年12月就诊于呼伦贝尔市中蒙医院的轻中度UC患者60例,随机分为对照组和治疗组,每组30例。对照组给予柳氮磺吡啶肠溶片口服,治疗组给予蒙药巴特日七味丸口服,2组疗程均为4周。比较2组患者治疗前后改良Mayo评分、红细胞沉降率(ESR)、血清炎症指标[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]和粪便钙卫蛋白(FC)水平、结肠组织中单核细胞趋化蛋白1(MCP-1)阳性表达情况和治疗4周后疗效、治疗期间不良反应发生情况。结果治疗后2组改良Mayo评分、ESR、血清CRP和TNF-α水平、粪便FC水平、结肠组织中MCP-1阳性表达平均光密度值均较治疗前明显降低(P均<0.05),且治疗组各指标均明显低于对照组(P均<0.05);治疗组治疗总有效率明显高于对照组[93.3%(28/30)比73.3%(22/30),P<0.05];2组治疗期间均无明显不良反应发生。结论蒙药巴特日七味丸可有效缓解轻中度UC患者临床症状,促进肠黏膜愈合,作用可能与其下调肠黏膜中MCP-1表达,抑制炎症反应有关。

Objective It is to investigate the clinical efficacy and possible mechanisms of the Mongolian medicine Bartezhi Qiwei Pill in the treatment of patients with mild to moderate ulcerative colitis(UC).Methods Sixty patients with mild-to-moderate UC treated in Hulunbeier Hulunbeier Hospital of Traditional Chinese and Mongolian medicine from September 2022 to December 2023 were included,and were randomly divided into a control group and a treatment group,with 30 patients in each group.The control group was given salicylazosulfapyridine enteric-coated tablets for oral administration,and the treatment group was given the Mongolian medicine Bartezhi Qiwei Pill for oral administration,both groups were treated for 4 weeks.The modified Mayo score,erythrocyte sedimentation rate(ESR),serum levels of inflammatory indexes[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]and fecal calreticulin(FC),and the positive expression of monocyte chemotactic protein 1(MCP-1)in colonic tissues of patients were compared between the two groups before and after treatment.Results After treatment,the modified Mayo scores,ESR,serum levels of CRP and TNF-α,fecal FC,and the mean optical density value of MCP-1 positive expression in colonic tissue were significantly lower than those before treatment in the two groups(all P<0.05),and all the indexes of the treatment group were significantly lower than those of the control group(all P<0.05);the total effective rate of treatment of the treatment group was significantly higher than that of the control group[93.3%(28/30)VS.73.3%(22/30),P<0.05];there was no significant adverse reaction occurred during the treatment period in both groups.Conclusion Mongolian medicine Bartezhi Qiwei Pill can effectively alleviate clinical symptoms and promote intestinal mucosal healing in patients with mild to moderate UC,and its effect may be related to down-regulating MCP-1 expression in intestinal mucosa and inhibiting inflammatory response.